We therefore felt appropriate to evaluate the potential role of the non-FDG tracer 18 F-choline in imaging of salivary gland tumors.Our goal was to evaluate the added value of a potentially more specific radiotracer. MethodsAfter obtaining ethics review board approval and informed consent of the patients, we prospectively included patients with clinical and cytological strong suspicion of malignant salivary gland tumors.All patients underwent hybrid FDG-PET followed by hybrid choline-PET.Surgery was offered as a primary treatment modality in resectable cases.Surgical pathology was reviewed by a dedicated head and neck pathologist (NJR) and classified pursuant to the 2017 update of the WHO classification [3]. ResultsThe cohort included five prospectively enrolled patients (Table 1).Four cases had cytologically proven malignant (Milan category VI) salivary gland neoplasms.In addition, one case of cytological "salivary gland neoplasm of uncertain malignant potential" (SUMP; Milan category IVb) was included [7].On final pathology, one case was a parotid gland highgrade mucoepidermoid carcinoma, one case of classical (low-grade) acinic cell carcinoma, one case of high-grade adenocarcinoma NOS, which would be classified as (high-grade) mucinous adenocarcinoma according to the forthcoming WHO 2023 classification.The other
No takes yet. Share an insight, caveat, or question.
Morand et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: